Long-term outcomes and predictors of vedolizumab persistence in ulcerative colitis

Background: Long-term vedolizumab (VDZ) outcomes in real-world cohorts have been largely limited to 1-year follow-up, with few bio-naïve patients or objective markers of inflammation assessed. Objectives: We aimed to assess factors affecting VDZ persistence including clinical, biochemical and faecal...

Popoln opis

Bibliografske podrobnosti

Principais autores:	Beatriz Gros, Hannah Ross, Maureen Nwabueze, Nathan Constantine-Cooke, Lauranne A. A. P. Derikx, Mathew Lyons, Claire O’Hare, Colin Noble, Ian D. Arnott, Gareth-Rhys Jones, Charlie W. Lees, Nikolas Plevris
Format:	Artigo
Jezik:	Inglês
Izdano:	SAGE Publishing 2024-07-01
Serija:	Therapeutic Advances in Gastroenterology
Online dostop:	https://doi.org/10.1177/17562848241258372
Oznake:	Označite Brez oznak, prvi označite!